ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3037% below fair value
$13.24+0.05 (+0.38%)
Close on Nov 12, 2026Market cap $2.97BP/E 17.2Yield –
ADMA Biologics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
ADMA Biologics's EV/EBITDA was 13.1× on Nov 11, 2026, against 26.2× a year earlier. Over the last 3 years it ranged from 8.6× to 124.3×, with a median of 27.5×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 13.1× | −11.8 |
| 2025 | Dec 31, 2025 | 24.9× | −7.5 |
| 2024 | Dec 31, 2024 | 32.4× | −74.8 |
| 2023 | Dec 29, 2023 | 107.1× | – |
See a number that looks wrong?